West Nile Virus (Flavivirus)

Overview

Plain-Language Overview

West Nile Virus (WNV) is a virus spread to people primarily through the bite of infected mosquitoes. It mainly affects the nervous system, causing symptoms that range from mild fever to severe neurological problems. Most people infected with WNV have no symptoms or only mild illness, but some develop serious conditions like encephalitis or meningitis, which involve inflammation of the brain or its surrounding tissues. The virus can cause headache, muscle weakness, and sometimes paralysis. It is important to understand that WNV is a seasonal illness, most common in the summer and early fall when mosquitoes are active.

Clinical Definition

West Nile Virus (WNV) is a single-stranded RNA virus of the Flavivirus genus transmitted by Culex mosquitoes. It causes a spectrum of disease from asymptomatic infection to severe neuroinvasive disease, including meningitis, encephalitis, and acute flaccid paralysis. The virus primarily targets the central nervous system, leading to inflammation and neuronal injury. Risk factors for severe disease include advanced age and immunosuppression. The infection is characterized by an initial febrile illness followed by neurological symptoms in severe cases. Diagnosis relies on detection of WNV-specific IgM antibodies in serum or cerebrospinal fluid. WNV is a significant cause of arboviral encephalitis in endemic regions, with potential for outbreaks during mosquito season.

Inciting Event

Bite from an infected Culex mosquito introduces West Nile virus into the bloodstream.
Blood transfusion or organ transplantation from infected donors can transmit the virus.
Vertical transmission from mother to fetus is rare but documented.
Exposure to infected birds or other reservoir hosts maintains the viral cycle in nature.

Latency Period

Incubation period ranges from 2 to 14 days after mosquito bite.
Symptom onset typically occurs within 3 to 6 days post-exposure.
Neuroinvasive symptoms may develop several days after initial febrile illness.

Diagnostic Delay

Initial symptoms are often nonspecific flu-like illness, leading to misdiagnosis.
Lack of awareness in non-endemic areas delays consideration of West Nile virus infection.
Serologic testing may be delayed due to need for specialized labs and cross-reactivity with other flaviviruses.
Neuroinvasive disease may be mistaken for other causes of meningitis or encephalitis.

Patient Population

Older adults are most commonly affected by severe neuroinvasive West Nile virus disease.
Immunocompromised individuals have higher risk of symptomatic and severe infection.
Cases peak in late summer to early fall in temperate regions due to mosquito activity.
Both males and females are affected, with a slight male predominance in severe cases.

Risk Factors

Advanced age (>60 years) significantly increases risk of severe neuroinvasive disease.
Immunosuppression (e.g., transplant recipients, HIV infection) predisposes to more severe infection.
Living in or traveling to endemic areas during mosquito season increases exposure risk.
Outdoor activities at dawn or dusk increase likelihood of mosquito bites transmitting the virus.
Chronic medical conditions such as diabetes and hypertension are associated with worse outcomes.

Clinical Presentation

Signs & Symptoms

Fever, headache, and fatigue are common initial symptoms.
Rash typically presents as a maculopapular eruption on the trunk and extremities.
Neuroinvasive symptoms include neck stiffness, confusion, seizures, and muscle weakness.
Gastrointestinal symptoms such as nausea and vomiting may occur.
Flaccid paralysis resembling poliomyelitis is a hallmark of severe neuroinvasive disease.

History of Present Illness

Initial presentation includes fever, headache, myalgias, and malaise lasting about a week.
Approximately 1 in 150 infected develop neuroinvasive disease with symptoms like neck stiffness, altered mental status, and weakness.
Some patients progress to acute flaccid paralysis resembling poliomyelitis.
Rash may occur in some cases, typically a maculopapular rash on the trunk and limbs.
Symptoms can progress rapidly over days to severe encephalitis or meningitis.

Past Medical History

History of immunosuppressive conditions or therapies increases risk of severe disease.
Prior chronic illnesses such as diabetes or cardiovascular disease worsen prognosis.
No specific prior infections are required but history of mosquito exposure is relevant.
Previous vaccination or infection with related flaviviruses may affect serologic interpretation.

Family History

No known heritable genetic predisposition to West Nile virus infection or severity.
Family clustering is rare and usually reflects shared environmental exposure rather than genetic factors.
No familial syndromes have been associated with increased susceptibility to West Nile virus.

Physical Exam Findings

Fever and maculopapular rash are common in West Nile virus infection.
Meningeal signs such as neck stiffness and photophobia may be present in neuroinvasive disease.
Muscle weakness and flaccid paralysis can be observed in cases of poliomyelitis-like syndrome.
Tremors and movement disorders such as parkinsonism may be noted in encephalitis.
Altered mental status ranging from confusion to coma is typical in severe neuroinvasive cases.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of West Nile Virus infection is established by detecting WNV-specific IgM antibodies in the serum or cerebrospinal fluid (CSF) using enzyme-linked immunosorbent assay (ELISA). The presence of IgM in CSF is highly suggestive of neuroinvasive disease. PCR testing for viral RNA may be used but is less sensitive due to transient viremia. Clinical presentation with fever, neurological symptoms, and epidemiological exposure to mosquitoes in endemic areas supports the diagnosis. Neuroimaging and CSF analysis may show findings consistent with meningitis or encephalitis but are not specific.

Pathophysiology

Key Mechanisms

Neuroinvasion by West Nile virus, a mosquito-borne Flavivirus, leads to neuronal injury and inflammation in the central nervous system.
Viral replication in neurons triggers a host immune response causing cytokine-mediated neurotoxicity.
Disruption of the blood-brain barrier facilitates viral entry into the CNS and contributes to encephalitis.
Direct viral cytopathic effects and immune-mediated damage cause meningoencephalitis and acute flaccid paralysis.

Involvement	Details
Organs	Brain involvement leads to clinical manifestations such as meningitis, encephalitis, and acute flaccid paralysis.
	Lymph nodes serve as sites of early viral replication and immune cell activation.
	Spinal cord involvement causes motor neuron damage resulting in flaccid paralysis.
Tissues	Central nervous system tissue is the primary site of viral invasion causing encephalitis and meningitis.
Tissues	Lymphoid tissue is involved in initial viral replication and immune activation.
Cells	Macrophages serve as primary host cells for West Nile Virus replication and dissemination.
	Neurons are targeted by the virus leading to encephalitis and neurological symptoms.
	Microglia mediate the neuroinflammatory response contributing to CNS damage.
Chemical Mediators	Interferon-alpha plays a critical role in the innate immune response limiting viral replication.
	Proinflammatory cytokines such as TNF-alpha and IL-6 contribute to neuroinflammation and symptom severity.
	Chemokines recruit immune cells to infected tissues, exacerbating inflammation.

Treatments

Pharmacological Treatments

Non-pharmacological Treatments

Supportive care including hydration and pain control is the mainstay of treatment for West Nile Virus infection.
Mechanical ventilation may be required in cases of severe neurologic involvement such as encephalitis or acute flaccid paralysis.
Physical therapy is important for recovery from neuromuscular weakness caused by the virus.

Prevention

Pharmacological Prevention

No approved antiviral agents or vaccines are currently available for West Nile virus prevention.
Passive immunization with immune globulin is investigational and not routinely used.

Non-pharmacological Prevention

Mosquito control measures including insecticide spraying and elimination of standing water reduce transmission.
Personal protective measures such as wearing long sleeves and using insect repellents containing DEET are effective.
Avoiding outdoor activities during peak mosquito activity at dawn and dusk decreases exposure risk.
Screening blood donations for West Nile virus prevents transfusion-related transmission.

Outcome & Complications

Complications

West Nile virus neuroinvasive disease including meningitis, encephalitis, and acute flaccid paralysis.
Seizures and status epilepticus can complicate encephalitis.
Respiratory failure may occur due to diaphragmatic weakness in poliomyelitis-like syndrome.
Secondary bacterial infections can develop due to prolonged hospitalization.
Death is a risk in severe neuroinvasive cases, especially in elderly or immunocompromised patients.

Short-term Sequelae	Long-term Sequelae
Prolonged fatigue and weakness are common after acute infection. Cognitive dysfunction and memory impairment may persist following encephalitis. Residual muscle weakness or paralysis can remain after acute flaccid paralysis. Post-infectious headaches and mood disturbances are frequently reported.	Chronic neurological deficits including persistent weakness and movement disorders. Cognitive impairment and neuropsychiatric symptoms may last months to years. Permanent paralysis can result from anterior horn cell damage. Depression and anxiety disorders are common in survivors of neuroinvasive disease.

Differential Diagnoses

West Nile Virus (Flavivirus) versus Japanese Encephalitis Virus

West Nile Virus (Flavivirus)	Japanese Encephalitis Virus
Exposure to mosquito bites in North America during summer or early fall	Travel or residence in rural Asia with exposure to rice paddies and pig farming
Positive IgM antibodies specific to West Nile virus in CSF or serum	Positive IgM antibodies specific to Japanese encephalitis virus in CSF or serum
Often self-limited with lower mortality but can cause meningoencephalitis	Higher mortality and more frequent progression to severe encephalitis

West Nile Virus (Flavivirus) versus Herpes Simplex Virus Encephalitis

West Nile Virus (Flavivirus)	Herpes Simplex Virus Encephalitis
MRI may show basal ganglia or thalamic involvement without temporal lobe predominance	MRI shows temporal lobe hyperintensities and hemorrhagic necrosis
Positive West Nile virus IgM in CSF or serum	Positive HSV PCR in CSF
Subacute onset with fever, headache, and possible flaccid paralysis	Rapid onset with focal neurological deficits and seizures

West Nile Virus (Flavivirus) versus La Crosse Virus Encephalitis

West Nile Virus (Flavivirus)	La Crosse Virus Encephalitis
Exposure to mosquitoes in broader geographic areas including urban and suburban regions	Exposure to mosquitoes in wooded areas of the upper Midwest and mid-Atlantic US
More common in older adults but can affect all ages	Primarily affects children and adolescents
Positive IgM antibodies to West Nile virus in CSF or serum	Positive IgM antibodies to La Crosse virus in CSF or serum

West Nile Virus (Flavivirus) versus Enteroviral Meningitis

West Nile Virus (Flavivirus)	Enteroviral Meningitis
Frequently causes meningoencephalitis with neurological deficits	Typically presents with aseptic meningitis symptoms without encephalitis
Positive West Nile virus IgM in CSF or serum	Positive enterovirus PCR in CSF
Can affect all ages, often adults and elderly	More common in infants and young children

West Nile Virus (Flavivirus) versus Tick-borne Encephalitis Virus

West Nile Virus (Flavivirus)	Tick-borne Encephalitis Virus
History of mosquito bites in endemic areas of North America	History of tick bites in endemic areas of Europe and Asia
Positive IgM antibodies to West Nile virus in CSF or serum	Positive IgM antibodies to tick-borne encephalitis virus in serum or CSF
Often monophasic illness with fever and neurological symptoms	Biphasic illness with initial febrile phase followed by neurological symptoms